Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Risperidone Implants in Schizophrenia
NCT02773576Phase 3Completed
- Sponsor
- Braeburn Pharmaceuticals
- Start
- Apr 2016
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of risperidone in schizophrenia, sponsored by Braeburn Pharmaceuticals. Started Apr 2016; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02773576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02773576.